Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arecor Ltd.

Improving delivery of biologics

This article was originally published in Start Up

Executive Summary

Arecor Ltd.'s Arestat technology is designed to improve the stability of biologics that otherwise can't be formulated as a liquid, because they are too unstable or the required protein concentration means that the viscosity is too high. Arecor's platform allows its collaborators to develop new products, cut their development and manufacturing costs, or gain a competitive advantage by creating a ready-to-use formulation that can be given as a smaller or faster-acting dose.

You may also be interested in...



Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer

Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.

PeptiMimesis

PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways

Redx Pharma PLC

Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092586

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel